CytoReason, an Israeli AI drug discovery startup, has raised $80 million in a funding round backed by Nvidia, Pfizer, OurCrowd, and Thermo Fisher Scientific to accelerate the development of its AI-powered platform for disease modeling and drug discovery.
Key details of CytoReason’s funding and expansion plans: The startup plans to use the funds to invest in expanding the application of its computational disease models, grow its proprietary data, and open a new office in Cambridge, Massachusetts later this year.
- CytoReason’s platform uses AI to extract insights from human disease data, helping pharma researchers make data-driven decisions and uncover potential therapeutic targets across multiple diseases.
- By simulating human diseases at the cellular level, CytoReason’s platform enables observation of how potential treatments interact with the human body, accelerating the drug development process.
Collaborations and industry impact: CytoReason has been working with Pfizer since 2019, and the pharma giant has taken a $20 million equity stake in the startup, securing the ability to license its platform and disease models as part of a $110 million deal.
- CytoReason claims to work with six of the world’s top 10 pharma companies, utilizing its platform across various therapeutic areas such as inflammation, therapeutics, and immunology.
- Pfizer’s chief scientific officer, Mikael Dolsten, highlighted the value of CytoReason’s platform in augmenting the company’s research and development capabilities and generating insights for new drug development pathways.
Leveraging cutting-edge technology: CytoReason uses Nvidia’s computing and AI platforms to power its work, achieving a 10-fold acceleration in inference of its workloads.
- Kimberly Powell, Nvidia’s general manager for health care, emphasized the potential for more life sciences companies to benefit from CytoReason’s predictive clinical insights through their continued collaboration.
Broader implications for AI-powered drug discovery: CytoReason’s successful funding round and collaborations with leading pharma companies underscore the growing importance of AI in accelerating drug discovery and development.
- The startup’s platform demonstrates the potential for AI to extract valuable insights from complex disease data, enabling researchers to identify promising therapeutic targets more efficiently.
- As more pharma companies embrace AI-powered solutions like CytoReason’s platform, the industry could see faster and more targeted drug development, ultimately benefiting patients in need of innovative treatments.
Recent Stories
DOE fusion roadmap targets 2030s commercial deployment as AI drives $9B investment
The Department of Energy has released a new roadmap targeting commercial-scale fusion power deployment by the mid-2030s, though the plan lacks specific funding commitments and relies on scientific breakthroughs that have eluded researchers for decades. The strategy emphasizes public-private partnerships and positions AI as both a research tool and motivation for developing fusion energy to meet data centers' growing electricity demands. The big picture: The DOE's roadmap aims to "deliver the public infrastructure that supports the fusion private sector scale up in the 2030s," but acknowledges it cannot commit to specific funding levels and remains subject to Congressional appropriations. Why...
Oct 17, 2025Tying it all together: Credo’s purple cables power the $4B AI data center boom
Credo, a Silicon Valley semiconductor company specializing in data center cables and chips, has seen its stock price more than double this year to $143.61, following a 245% surge in 2024. The company's signature purple cables, which cost between $300-$500 each, have become essential infrastructure for AI data centers, positioning Credo to capitalize on the trillion-dollar AI infrastructure expansion as hyperscalers like Amazon, Microsoft, and Elon Musk's xAI rapidly build out massive computing facilities. What you should know: Credo's active electrical cables (AECs) are becoming indispensable for connecting the massive GPU clusters required for AI training and inference. The company...
Oct 17, 2025Vatican launches Latin American AI network for human development
The Vatican hosted a two-day conference bringing together 50 global experts to explore how artificial intelligence can advance peace, social justice, and human development. The event launched the Latin American AI Network for Integral Human Development and established principles for ethical AI governance that prioritize human dignity over technological advancement. What you should know: The Pontifical Academy of Social Sciences, the Vatican's research body for social issues, organized the "Digital Rerum Novarum" conference on October 16-17, combining academic research with practical AI applications. Participants included leading experts from MIT, Microsoft, Columbia University, the UN, and major European institutions. The conference...